Bladder Cancer | Current Treatment: Physician Insights | US | 2021

Immune checkpoint inhibitors have experienced tremendous uptake in the treatment of bladder cancer following their approval for metastatic disease and, in the case of Keytruda, non-muscle-invasive disease. The addition of Merck KGaA / Pfizer’s Bavencio as first-line maintenance therapy for metastatic or unresectable bladder cancer will continue to drive uptake. These therapies have significantly transformed the treatment algorithm for the disease in all lines of therapy, particularly the cisplatin-ineligible population. The approval of novel drug classes, such as Janssen’s first-in-class FGFR inhibitor Balversa (erdafitinib) for patients harboring susceptible FGFR2 or FGFR3 genetic alterations and Astellas / Seagen’s antibody drug conjugate (ADC) Padcev (enfortumab vedotin-ejfv) for locally advanced unresectable or metastatic disease, will further expand physicians’ armamentarium.


  • What percentage of non-muscle-invasive bladder cancer patients receive maintenance BCG, and how does this treatment vary by stage and histologic grade?
  • What is the uptake of immune checkpoint inhibitors in the United States across therapy lines? How are immune checkpoint inhibitors faring against older (e.g., platinum-based chemotherapy) and newer therapies (e.g., Balversa, Padcev)?
  • What clinical factors drive the use of Merck KGaA / Pfizer’s Bavencio as maintenance therapy for unresectable locally advanced or metastatic disease?
  • How do drug-treatment rates vary across key patient populations and treatment lines?
  • What are the main drivers of and obstacles to treatment with key drugs for unresectable locally advanced or metastatic bladder cancer?


Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Markets covered: United States

Key companies: Astellas / Seagen, AstraZeneca, Bristol Myers Squibb, Genentech / Roche, Janssen, Merck & Co., Merck KGaA / Pfizer

Key drugs: Balversa, Bavencio, Imfinzi, Keytruda, Opdivo, Padcev, Tecentriq

Login to access report